Home HIV	FAQ My Amedeo About	Flying Publisher
	Amedeo Prize 2008 The 21 Finalists

Lung Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 71 articles: HTML format

Single Articles

April 2008
1. XING J , Stewart DJ, Gu J, Lu C, et al
   Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer.
   Br J Cancer. 2008;.
   PubMed     Related articles    Abstract available
   
   
   February 2008
2. NAVANI N , Janes SM
   Contemporary issues in cancer imaging: lung cancer.
   Br J Cancer. 2008;98:855.
   PubMed     Related articles   
   
   
   
3. TAMURA K , Okamoto I, Kashii T, Negoro S, et al
   Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
   Br J Cancer. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
4. KIM DW , Min HS, Lee KH, Kim YJ, et al
   High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected nonsmall cell lung cancer.
   Br J Cancer. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
5. SHIMIZU Y , Kinoshita I, Kikuchi J, Yamazaki K, et al
   Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant.
   Br J Cancer. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
6. MAEDA J , Hirano T, Ogiwara A, Akimoto S, et al
   Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
   Br J Cancer. 2008;98:596-603.
   PubMed     Related articles    Abstract available
   
   
   
7. AKASHI Y , Okamoto I, Iwasa T, Yoshida T, et al
   Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.
   Br J Cancer. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
8. SEKINE I , Nokihara H, Takeda K, Nishiwaki Y, et al
   Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.
   Br J Cancer. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
9. KAIRA K , Oriuchi N, Imai H, Shimizu K, et al
   Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer.
   Br J Cancer. 2008;.
   PubMed     Related articles    Abstract available
   
   
   January 2008
10. TIBALDI C , Vasile E, Antonuzzo A, Di Marsico R, et al
    First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study.
    Br J Cancer. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
11. SAVIC S , Tapia C, Grilli B, Rufle A, et al
    Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.
    Br J Cancer. 2008;98:154-60.
    PubMed     Related articles    Abstract available
    
    
    December 2007
12. OLSEN JH , Friis S, Poulsen AH, Fryzek J, et al
    Use of NSAIDs, smoking and lung cancer risk.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
13. NISMAN B , Biran H, Heching N, Barak V, et al
    Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
14. CASSIDY A , Myles JP, van Tongeren M, Page RD, et al
    The LLP risk model: an individual risk prediction model for lung cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    November 2007
15. THIES A , Dautel P, Meyer A, Pfuller U, et al
    Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
16. ZOU L , Jaramillo M, Whaley D, Wells A, et al
    Profilin-1 is a negative regulator of mammary carcinoma aggressiveness.
    Br J Cancer. 2007;97:1361-71.
    PubMed     Related articles    Abstract available
    
    
    
17. PALLIS AG , Voutsina A, Kalikaki A, Souglakos J, et al
    'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    October 2007
18. DE GROOT DJ , van der Deen M, Le TK, Regeling A, et al
    Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1.
    Br J Cancer. 2007;97:1077-83.
    PubMed     Related articles    Abstract available
    
    
    
19. LI KM , Rivory LP, Clarke SJ
    Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.
    Br J Cancer. 2007;97:1071-6.
    PubMed     Related articles    Abstract available
    
    
    September 2007
20. FESKANICH D , Bain C, Chan AT, Pandeya N, et al
    Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
21. PIRA E , Pelucchi C, Piolatto PG, Negri E, et al
    First and subsequent asbestos exposures in relation to mesothelioma and lung cancer mortality.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
22. KIMURA H , Suminoe M, Kasahara K, Sone T, et al
    Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
    Br J Cancer. 2007;97:778-84.
    PubMed     Related articles    Abstract available
    
    
    
23. VLAHOVIC G , Ponce AM, Rabbani Z, Salahuddin FK, et al
    Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.
    Br J Cancer. 2007;97:735-40.
    PubMed     Related articles    Abstract available
    
    
    
24. XU W , Soga S, Beebe K, Lee MJ, et al
    Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.
    Br J Cancer. 2007;97:741-4.
    PubMed     Related articles    Abstract available
    
    
    August 2007
25. MELLOR P , Harvey JR, Murphy KJ, Pye D, et al
    Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
26. HSIEH AC , Moasser MM
    Targeting HER proteins in cancer therapy and the role of the non-target HER3.
    Br J Cancer. 2007;97:453-7.
    PubMed     Related articles    Abstract available
    
    
    
27. HELBEKKMO N , Sundstrom SH, Aasebo U, Brunsvig PF, et al
    Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.
    Br J Cancer. 2007;97:283-9.
    PubMed     Related articles    Abstract available
    
    
    July 2007
28. EL-KHOURY V , Breuzard G, Fourre N, Dufer J, et al
    The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
29. MA PC , Tretiakova MS, Nallasura V, Jagadeeswaran R, et al
    Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
    Br J Cancer. 2007;97:368-77.
    PubMed     Related articles    Abstract available
    
    
    
30. LORCH G , Gilmore JL, Koltz PF, Gonterman RM, et al
    Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice.
    Br J Cancer. 2007;97:183-93.
    PubMed     Related articles    Abstract available
    
    
    
31. AGUAYO F , Castillo A, Koriyama C, Higashi M, et al
    Human papillomavirus-16 is integrated in lung carcinomas: a study in Chile.
    Br J Cancer. 2007;97:85-91.
    PubMed     Related articles    Abstract available
    
    
    
32. SUN CK , Ng KT, Sun BS, Ho JW, et al
    The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence.
    Br J Cancer. 2007;97:50-7.
    PubMed     Related articles    Abstract available
    
    
    June 2007
33. BELDERBOS J , Baas P, Senan S
    Reply: Patterns of nodal recurrence after omission of elective nodal irradiation for limited-stage small-cell lung cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles   
    
    
    
34. CHIEN CR , Yu CJ
    Involved-field radiotherapy in limited-stage small-cell lung cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles   
    
    
    
35. OKAMOTO H , Watanabe K, Kunikane H, Yokoyama A, et al
    Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    May 2007
36. MATAKIDOU A , El Galta R, Rudd MF, Webb EL, et al
    Prognostic significance of folate metabolism polymorphisms for lung cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
37. MATAKIDOU A , El Galta R, Rudd MF, Webb EL, et al
    Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
38. AKASHI Y , Okamoto I, Suzuki M, Tamura K, et al
    The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo.
    Br J Cancer. 2007;96:1532-9.
    PubMed     Related articles    Abstract available
    
    
    
39. KUNITOH H , Suzuki K
    How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
40. BERGHMANS T , Lafitte JJ, Lecomte J, Alexopoulos CG, et al
    Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    April 2007
41. LEMOS-GONZALEZ Y , Rodriguez-Berrocal FJ, Cordero OJ, Gomez C, et al
    Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
42. BABIAK A , Hetzel J, Godde F, Konig HH, et al
    Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a phase II trial.
    Br J Cancer. 2007;96:1052-6.
    PubMed     Related articles    Abstract available
    
    
    
43. BELINSKY SA , Grimes MJ, Casas E, Stidley CA, et al
    Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    March 2007
44. SATOUCHI M , Negoro S, Funada Y, Urata Y, et al
    Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
45. NERI B , Pantaleo P, Giommoni E, Grifoni R, et al
    Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
46. HUDSON E , Powell J, Mukherjee S, Crosby TD, et al
    Small cell oesophageal carcinoma: an institutional experience and review of the literature.
    Br J Cancer. 2007;96:708-11.
    PubMed     Related articles    Abstract available
    
    
    
47. PATEL N , Adatia R, Mellemgaard A, Jack R, et al
    Variation in the use of chemotherapy in lung cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    February 2007
48. URAMOTO H , Mitsudomi T
    Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
49. FORGET MA , Turcotte S, Beauseigle D, Godin-Ethier J, et al
    The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types.
    Br J Cancer. 2007;96:646-53.
    PubMed     Related articles    Abstract available
    
    
    
50. FORD CE , Lau SK, Zhu CQ, Andersson T, et al
    Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    January 2007
51. THIES A , Mauer S, Fodstad O, Schumacher U, et al
    Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
52. BROOKS DR , Klint A, Dickman PW, Stahle E, et al
    Temporal trends in non-small cell lung cancer survival in Sweden.
    Br J Cancer. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
53. COSTA DB , Kobayashi S
    Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
    Br J Cancer. 2007;.
    PubMed     Related articles   
    
    
    
54. NEGRI T , Casieri P, Miselli F, Orsenigo M, et al
    Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
    Br J Cancer. 2007;96:180-1.
    PubMed     Related articles   
    
    
    
55. ASAHINA H , Yamazaki K, Kinoshita I
    Reply: Appropriate prospective trials are warranted to determine differences between exon 19 deletions and L858R epidermal growth factor receptor mutations in non-small cell lung cancer.
    Br J Cancer. 2007;.
    PubMed     Related articles   
    
    
    December 2006
56. YANG Y , Ikezoe T, Nishioka C, Bandobashi K, et al
    NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.
    Br J Cancer. 2006;95:1653-62.
    PubMed     Related articles    Abstract available
    
    
    November 2006
57. HONG YS , Lee HR, Park S, Lee SC, et al
    Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
58. KIMURA H , Fujiwara Y, Sone T, Kunitoh H, et al
    EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Br J Cancer. 2006;95:1390-5.
    PubMed     Related articles    Abstract available
    
    
    
59. SUTANI A , Nagai Y, Udagawa K, Uchida Y, et al
    Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
60. JEUNG HC , Rha SY, Cho BC, Yoo NC, et al
    A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    October 2006
61. OSHITA F , Matsukuma S, Yoshihara M, Sakuma Y, et al
    Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer.
    Br J Cancer. 2006;95:1070-5.
    PubMed     Related articles    Abstract available
    
    
    
62. ASAHINA H , Yamazaki K, Kinoshita I, Sukoh N, et al
    A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
    Br J Cancer. 2006;95:998-1004.
    PubMed     Related articles    Abstract available
    
    
    
63. VON PLESSEN C , Bergman B, Andresen O, Bremnes RM, et al
    Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.
    Br J Cancer. 2006;95:966-73.
    PubMed     Related articles    Abstract available
    
    
    
64. VLAHOVIC G , Rabbani ZN, Herndon JE 2nd, Dewhirst MW, et al
    Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
    Br J Cancer. 2006;95:1013-9.
    PubMed     Related articles    Abstract available
    
    
    
65. GROSCHE B , Kreuzer M, Kreisheimer M, Schnelzer M, et al
    Lung cancer risk among German male uranium miners: a cohort study, 1946-1998.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
66. SATO K , Yuasa T, Nogawa M, Kimura S, et al
    A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
67. TAKIGAWA N , Kiura K, Segawa Y, Watanabe Y, et al
    Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    September 2006
68. CASSIDY A , Myles JP, Duffy SW, Liloglou T, et al
    Family history and risk of lung cancer: age-at-diagnosis in cases and first-degree relatives.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
69. NEGISHI T , Koizumi F, Uchino H, Kuroda J, et al
    NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel.
    Br J Cancer. 2006;95:601-6.
    PubMed     Related articles    Abstract available
    
    
    July 2006
70. MORRIS JK , George LM, Wu T, Wald NJ, et al
    Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies.
    Br J Cancer. 2006;95:112-7.
    PubMed     Related articles    Abstract available
    
    
    June 2006
71. CHANDANOS E , Lindblad M, Jia C, Rubio CA, et al
    Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden.
    Br J Cancer. 2006;.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: